These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Sirolimus lowers myeloperoxidase and p-ANCA titers in a pediatric patient before kidney transplantation. Constantinescu AR; Liang M; Laskow DA Am J Kidney Dis; 2002 Aug; 40(2):407-10. PubMed ID: 12148116 [TBL] [Abstract][Full Text] [Related]
4. Sirolimus in de novo heart transplant recipients with severe renal impairment. Vazquez de Prada JA; Vilchez FG; Cobo M; Ruisanchez C; Valls MF; Ruano J; Piñera C; Duran RM Transpl Int; 2006 Mar; 19(3):245-8. PubMed ID: 16441775 [TBL] [Abstract][Full Text] [Related]
5. Sirolimus and everolimus in kidney transplantation. Moes DJ; Guchelaar HJ; de Fijter JW Drug Discov Today; 2015 Oct; 20(10):1243-9. PubMed ID: 26050578 [TBL] [Abstract][Full Text] [Related]
7. The impact of sirolimus on sex hormones in male adolescent kidney recipients. Cavanaugh TM; Schoenemen H; Goebel J Pediatr Transplant; 2012 May; 16(3):280-5. PubMed ID: 22372519 [TBL] [Abstract][Full Text] [Related]
8. Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: comparison of two CNI-free protocols. Diekmann F; Gutiérrez-Dalmau A; López S; Cofán F; Esforzado N; Ricart MJ; Rossich E; Saval N; Torregrosa JV; Oppenheimer F; Campistol JM Nephrol Dial Transplant; 2007 Aug; 22(8):2316-21. PubMed ID: 17452413 [TBL] [Abstract][Full Text] [Related]
9. Patient selection critical for calcineurin inhibitor withdrawal in pediatric kidney transplantation. Weintraub L; Li L; Kambham N; Alexander S; Concepcion W; Miller K; Wong C; Salvatierra O; Sarwal M Pediatr Transplant; 2008 Aug; 12(5):541-9. PubMed ID: 18564305 [TBL] [Abstract][Full Text] [Related]
10. Long-term renal allograft survival after posttransplantation diagnosis of primary hyperoxaluria. Roberts V; Rajakumar SV; Crikis S; Dwyer KM; Hill PA; Goodman DJ Transplantation; 2013 Mar; 95(6):e35-6. PubMed ID: 23507654 [No Abstract] [Full Text] [Related]
11. Practical recommendations for the early use of m-TOR inhibitors (sirolimus) in renal transplantation. Campistol JM; Cockwell P; Diekmann F; Donati D; Guirado L; Herlenius G; Mousa D; Pratschke J; San Millán JC Transpl Int; 2009 Jul; 22(7):681-7. PubMed ID: 19386082 [TBL] [Abstract][Full Text] [Related]
12. Immunoregulatory effects of sirolimus vs. tacrolimus treatment in kidney allograft recipients. Gong N; Chen Z; Wang J; Fang A; Li Y; Xiang Y; Ming C; Zhang W Cell Immunol; 2015 Oct; 297(2):87-93. PubMed ID: 26205091 [TBL] [Abstract][Full Text] [Related]
13. Outcomes with conversion from calcineurin inhibitors to sirolimus after renal transplantation in the context of steroid withdrawal or steroid continuation. Egbuna OI; Davis RB; Chudinski R; Pavlakis M; Rogers C; Molakatalla P; Johnson SR; Karp S; Monaco AP; Tang H; Hanto DW; Mandelbrot DA Transplantation; 2009 Sep; 88(5):684-92. PubMed ID: 19741466 [TBL] [Abstract][Full Text] [Related]
14. Sirolimus protective effects on bone: the need to be demonstrated. Luo LM; Wang LL Nephrol Dial Transplant; 2012 Jun; 27(6):2602-3. PubMed ID: 22323528 [No Abstract] [Full Text] [Related]
15. Colonic perforation associated with leukocytoclastic vasculitis caused by Sirolimus toxicity following renal transplantation. Hugl B; Lhotta K; Ensinger C; Cont M; Kafka R; Margreiter R; Rosenkranz A; Bonatti H Transpl Int; 2006 May; 19(5):430-1. PubMed ID: 16623879 [No Abstract] [Full Text] [Related]